Loading…
← CockpitCompetitor Analysis › SBC SBC Medical Group Holdings IncorporatedOpen in the cockpit ↗

SBC Medical Group Holdings IncorporatedSBCCompetitor analysis, valuation and peers

United States · USD·Health Care›Miscellaneous Commercial Services
Momentum leader 99
Mkt cap
$645M
US dollars, full cap
Free float
18%
of shares outstanding
$/day
$2.21M
20-day average traded
Fwd P/E
11.7×
forward earnings
ROIC−WACC
+29.7 pp
WACC 7.5%
Hurdle
-22 pp
Req g minus delivered
Next earnings
128 days
26 Mar 2027
Close · USD$6.27
1D+2.5%
1W+19.7%
1M+14.8%
3M+70.4%
6M+94.1%
YTD+45.5%
1Y+106.6%
ATR %7.1%
Beta0.88
52w lowhigh15.2% off high

What SBC Medical does

Employees: 863

SBC Medical at a glance

Size SBC Medical (SBC) is a United States Health Care company (Miscellaneous Commercial Services) with a market value of $645M, the 2508th largest of 3,085 United States companies the cockpit tracks. Shares closed at $6.27 on 18 Nov 2026.

Performance Over six months the shares gained 94.1%, against -10.6% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 9 in its peer set.

Growth Revenue grew 6.7% over the last twelve months (peer median -3.4%); the operating margin is 39.9% (peer median -65.5%).

Valuation It trades at 11.7× forward earnings.

Price implies For today's price to make sense, revenue must grow about -16% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -22 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 29.7 points above its cost of capital (7.5% WACC).

Short interest Short interest is 0.8% of the free float (30 Oct 2026).

Next results Next results expected around 26 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015020021 May 202621 Aug 202618 Nov 2026SBC 202Peer median 89
Six months, rebased to 100: SBC Medical against the median of its 8 peers (local-currency closes).

SBC Medical financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$190M$174M$205M$194M$0
Revenue growth—-15%+6%——
Gross profit$136M$126M$154M$126M$0
EBITDA$79.6M$70.2M$89.2M$83.3M-$543,700
Net income$51.9M$51.0M$46.6M$39.4M$552,813
Free cash flow$113M$36.6M$51.9M$41.2M-$462,820
Capital expenditure$3.45M$2.79M$3.41M$11.2M$0
Total debt$44.0M$51.6M$12.2M$22.9M$0

Quarterly statements and history in the cockpit →

SBC Medical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%-20%-10%0%+10%ANLOABIEVTOCSEVHTECXSLNFTRESBC6-month return →1-month return →
Up and to the right = strong over both horizons. SBC Medical is the large dot.

Fundamentals: revenue growth against valuation

0%+5%+10%+15%10×15×20×EVHFTRESBCRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. SBC Medical is the large dot.

Capital: growth delivered against growth the price implies

-25%0%+25%+50%0%50%OABIEVHFTRESBCGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. SBC Medical is the large dot.

SBC Medical competitors and peer comparison

How SBC Medical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

SBC Medical against its 8 peers (data as of 18 Nov 2026)
MeasureSBCPeer medianRank in peer set
1-month return+14.8%-2.5%highest of 9
6-month return+94.1%-10.6%3rd highest of 9
Distance from 52-week high-15.2%-42.0%3rd highest of 9
Revenue growth (TTM)+6.7%-3.4%3rd highest of 6
Operating margin39.9%-65.5%highest of 7
Forward P/E11.7×n/a—
Growth the price implies (Req g, 7 yrs)-15.7%31.9%least demanding of 4
Growth delivered (Del g)+6.7%+1.1%2nd highest of 4
Hurdle (Req g minus delivered)-22.4 pp+30.9 ppleast demanding of 4
ROIC minus cost of capital+29.7 pp-13.6 pphighest of 5
EV / EBITDA6.3×n/a—
Net debt / EBITDA-2.0×n/a—

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
SBC Medical SBCUnited States$645M+94%+7%40%11.7×-15.7%+6.7%
Adlai Nortye Ltd. Sponsored ADR ANLUnited States$610M-23%n/a-134%n/an/an/a
OmniAb OABIUnited States$741M+97%+91%-116%n/a60.6%-31.9%
Evotec EVT.DEGermany$532M-46%-5%-15%n/an/an/a
Oculis OCSUnited States$456M-74%n/an/an/an/an/a
Evolent Health EVHUnited States$445M+2%+14%-1%9.2×14.0%+15.2%
Tectonic Therapeutic TECXUnited States$420M-27%n/an/an/an/an/a
Silence Therapeutics PLC Sponsored ADR SLNUnited States$1.23B+244%-98%-11,920%n/an/an/a
Fortrea FTREUnited States$1.98B+50%-3%2%21.6×31.9%+1.1%

Questions

Which companies are SBC Medical's closest peers?
The cockpit's peer set: Adlai Nortye Ltd. Sponsored ADR (ANL), OmniAb (OABI), Evotec (EVT.DE), Oculis (OCS), Evolent Health (EVH), Tectonic Therapeutic (TECX), Silence Therapeutics PLC Sponsored ADR (SLN), Fortrea (FTRE).
How has SBC Medical stock performed?
Over six months to 18 Nov 2026 the shares returned +94.1% against -10.6% for the median peer; over one year +106.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.